NEW YORK (TheStreet) -- Receptos
(RCPT - Get Report) shares exploded in market trading on Tuesday, climbing 36.7% to $39.94, after reporting positive results from the phase 2 study of its oral relapsing multiple sclerosis treatment RPC1063.
The trial met its primary endpoint of reducing the number of MRI detected number of total gadolinium-enhancing lesions from the 12th week - 24th week of treatment.
An estimated 2 million people suffer from multiple sclerosis with more than half of them residing in the United States and Europe.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.